Home › Type 1 Diabetes › NCT06883344
Automated Insulin for Management of Intrapartum Glycemia
Automated Insulin for Management of Intrapartum Glycemia (AIMING): a Multicenter Randomized Controlled Trial
Who can join
Ages 18 to 55 · Women
Full eligibility criteria
Inclusion Criteria: * Currently pregnant at ≥ 34 weeks * Known diagnosis of type 1 diabetes ≥ 1 year * Use of commercially available AID system since at least 28 weeks gestation * Singleton pregnancy * English- or Spanish-speaking Exclusion Criteria: * Multifetal gestation * Planned cesarean delivery * Use of medications known to interfere with glucose metabolism * Intrauterine fetal demise * Physical or psychological disease likely to interfere with the conduct of the study and/or the ability to participate in own healthcare
About the study
The goal of this clinical trial is learn if automated insulin delivery (AID) systems can be used for glucose management during labor/delivery for pregnant people with type 1 diabetes (T1D). The main questions this study aims to answer are
* What are the neonatal glycemic outcomes with use of AID systems during labor/delivery? * Do patients report higher birth satisfaction with use of AID systems during labor/delivery? * Are glycemic parameters like time-in-range (TIR) better with use of AID systems during labor/delivery?
Researchers will compare AID systems to intravenous (IV) insulin (the current standard of care for glucose management during labor/delivery) by randomly assigning participants to one or the other.
What is being tested
- Automated insulin delivery (AID) system (device)
- Intravenous (IV) insulin (other)
Sponsor: University of California, San Francisco · Participants: 150 · Started: Dec 5, 2025
Contact the study team
- DAPP Principal Investigator · Phone: (415) 307-9319
Official record on ClinicalTrials.gov — NCT06883344
Locations in the U.S.
| California | University of California, Los Angeles, Los Angeles University of California, San Diego, San Diego University of California, San Francisco, San Francisco |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.